Shenzhen Salubris Pharmaceuticals Co Ltd (002294)

Shenzhen

Currency in CNY

50.72

+0.19(+0.38%)

Delayed Data·04:30:00

Fair Value

Unlock Value

Day's Range

49.89

51.19

52 wk Range

27.51

55.48

002294 Income Statement

Featured here, the Income Statement (earnings report) for Shenzhen Salubris Pharmaceuticals Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2022

01/01

2023

01/01

2023

31/12

2024

31/12

Total Revenues

aa.aa

2,738.56

3,058.39

3,482.01

3,365.34

4,012.23

Total Revenues Growth

aa.aa

-38.74%

+11.68%

+13.85%

-3.35%

+19.22%

Cost Of Revenues

aa.aa

847.87

811.29

1,000.77

1,065.46

1,138.06

Gross Profit

aa.aa

1,890.69

2,247.1

2,481.24

2,299.88

2,874.17

Gross Profit Growth

aa.aa

-46.07%

+18.85%

+10.42%

-7.31%

+24.97%

Gross Profit Margin %

aa.aa

69.04%

73.47%

71.26%

68.34%

71.64%

Other Operating Expenses, Total

aa.aa

1,584.39

1,742.8

1,915.67

1,734.06

2,190.24

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-40.91%	+10%	+9.92%	-9.48%	+26.31%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	371.2	357.37	533.75	409.19	421.24
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,178.53	1,340.45	1,334.98	1,304.66	1,750.24
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	34.67	44.98	46.93	20.2	18.76

Operating Income

aa.aa

306.3

504.3

565.58

565.82

683.93

Operating Income Growth

aa.aa

-62.85%

+64.64%

+12.15%

+0.04%

+20.87%

EBIT Margin %

aa.aa

11.18%

16.49%

16.24%

16.81%

17.05%

Net Interest Expenses

aa.aa

17.93

171.37

138.72

63.57

63.92

Net Interest Expenses Growth

aa.aa

+55,057.67%

+855.67%

-19.05%

-54.17%

+0.55%

Interest Expense, Total

aa.aa

-17.57

-10.53

-12.54

-17.37

-16.17

Interest And Investment Income

aa.aa

35.5

181.9

151.26

80.94

80.09

Other Non Operating Expenses, Total

aa.aa

-26.81

-13.32

-0.29

2.57

0.32

EBT, Excl. Unusual Items

aa.aa

297.43

662.35

704

631.96

748.17

Gain (Loss) On Sale Of Assets

aa.aa

0.21

-1.3

-0.18

-0.48

-0.15

Other Unusual Items, Total

aa.aa

68.61

-61.21

32.7

51.8

-130.02

EBT, Incl. Unusual Items

aa.aa

56.74

599.84

713.73

641.76

632.52

EBT, Incl. Unusual Items Growth

aa.aa

-93.33%

+957.13%

+18.99%

-10.08%

-1.44%

EBT, Incl. Unusual Items Margin

aa.aa

2.07%

19.61%

20.5%

19.07%

15.76%

Income Tax Expense

aa.aa

6.61

71.52

79.36

60.93

27.36

Net Income to Company

aa.aa

50.13

528.32

634.37

580.83

605.16

Minority Interest

aa.aa

10.73

5.41

2.73

-0.76

-3.59

Net Income

aa.aa

60.86

533.73

637.09

580.07

601.57

Net Income Growth

aa.aa

-91.49%

+776.9%

+19.37%

-8.95%

+3.71%

Net Income Margin %

aa.aa

2.22%

17.45%

18.3%

17.24%

14.99%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

60.86

533.73

637.09

580.07

601.57

Basic EPS - Continuing Operations

aa.aa

0.06

0.5

0.58

0.52

0.54

Basic EPS - Continuing Operations Growth

aa.aa

-91.18%

+733.33%

+16%

-10.34%

+3.85%

Diluted EPS - Continuing Operations

aa.aa

0.06

0.5

0.58

0.52

0.54

Diluted EPS - Continuing Operations Growth

aa.aa

-91.18%

+733.33%

+16%

-10.34%

+3.85%

Basic Weighted Average Shares Outstanding

aa.aa

1,014.42

1,067.45

1,098.43

1,115.51

1,114.02

Diluted Weighted Average Shares Outstanding

aa.aa

1,014.42

1,067.45

1,098.43

1,115.51

1,114.02

Dividend Per Share

aa.aa

0.4

0.5

Dividend Per Share Growth

aa.aa

+25%

EBITDA

aa.aa

552.33

798.4

873.67

893.22

1,044.54

EBITDA Growth

aa.aa

-47.59%

+44.55%

+9.43%

+2.24%

+16.94%

EBITDA Margin %

aa.aa

20.17%

26.11%

25.09%

26.54%

26.03%

EBIT

aa.aa

306.3

504.3

565.58

565.82

683.93

* In Millions of CNY (except for per share items)

NSE 30

5,110.26

+51.12

+1.01%

NSE All Share

139,278.67

+1,365.80

+0.99%

US 30

44,593.30

+132.0

+0.30%

US 500

6,423.70

+60.8

+0.95%

FTSE 100

9,136.94

+0.62

+0.01%

DAX

24,262.22

+44.85

+0.19%

South Africa Top 40

91,597.63

+76.89

+0.08%

Market Movers

Name	Last	Chg. %	Vol.
Fidelitybk	21.000	+2.44%	90.40M
Guaranty Trust Holding	101.95	+4.03%	30.26M
Nigerian Breweries	77.00	+4.05%	29.34M
Nascon	99.90	+8.59%	16.82M
Lafarge Africa	151.00	+7.63%	14.59M
MTN Nigeria	471.10	+4.32%	6.99M
Dangote Cement	509.60	0.00%	3.59M

Name	Last	Chg. %	Vol.
Multverse	9.90	+10.00%	843.76K
Royalex	1.54	+10.00%	25.12M
Npfmcrfbk	3.420	+9.97%	11.86M
Dangote Sugar	71.15	+9.97%	7.69M
Berger Paints	37.50	+9.97%	2.92M
UAC Of Nigeria	73.00	+9.94%	2.99M
Mecure Industries	14.45	+9.89%	2.18M

Name	Last	Chg. %	Vol.
FTN Cocoa Processors PLC	6.30	-10.00%	13.97M
Abbey Mortgage Bank	6.48	-10.00%	754.65K
Livingtrust Mortgage Bank	6.59	-9.97%	103.95K
Sunu Assurances	4.14	-9.61%	11.72M
Consolidated Hallmark	3.20	-7.78%	10.38M
Honeywell Flour Mills Plc	25.050	-7.22%	13.78M
Tantalizers	2.51	-7.04%	4.98M

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	471.10	+4.32%	6.99M
Guaranty Trust Holding	101.95	+4.03%	30.26M
Okomu Oil Palm	1,050.00	0.00%	385.41K
Lafarge Africa	151.00	+7.63%	14.59M
Access Holdings	27.60	+1.47%	43.05M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaa Aaaaaaaaa	509.60	+38.81%	707.38
Aaaaaaaaaaaaaaaa	5,450.00	+30.99%	7,138.95
A Aaaaa	66.50	+25.53%	83.48
Aaaaaaaaaa	135.00	+24.29%	167.79

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Shenzhen Salubris Pharmaceuticals Co Ltd (002294)

002294 Income Statement

Trending Stocks